Allogene Therapeutics, Inc.
NASDAQ:ALLO
2.91 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Assets: | |||||||
| Current Assets: | |||||||
| Cash & Cash Equivalents
| 83.155 | 576.471 | 809.481 | 1,032.118 | 588.855 | 721.35 | 0 |
| Short Term Investments
| 365.542 | 455.416 | 283.988 | 644.559 | 355.407 | 366.952 | 0 |
| Cash and Short Term Investments
| 448.697 | 576.471 | 809.481 | 1,032.118 | 588.855 | 721.35 | 0 |
| Net Receivables
| 1.7 | 3.3 | 6 | 2.8 | 2.403 | 3.108 | 0 |
| Inventory
| -1.7 | -62.451 | -20.021 | -207.008 | -60.725 | -261.966 | 0 |
| Other Current Assets
| 10.418 | 11.504 | 14.021 | 17.22 | 14.043 | 5.49 | 0 |
| Total Current Assets
| 459.115 | 528.824 | 809.481 | 845.13 | 544.576 | 467.982 | 0 |
| Non-Current Assets: | |||||||
| Property, Plant & Equipment, Net
| 163.181 | 196.431 | 181.02 | 160.135 | 100.944 | 41.61 | 0 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0.151 | 0.754 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0.151 | 0.754 | 0 |
| Long Term Investments
| 3.645 | 59.151 | 370.184 | 207.946 | 63.214 | 261.966 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 16.896 | 32.673 | -322.051 | 14.618 | 8.917 | 1.543 | 0 |
| Total Non-Current Assets
| 183.722 | 288.255 | 229.153 | 382.699 | 173.226 | 305.873 | 0 |
| Total Assets
| 642.837 | 817.079 | 1,038.634 | 1,227.829 | 717.802 | 773.855 | 0 |
| Liabilities & Equity: | |||||||
| Current Liabilities: | |||||||
| Account Payables
| 5.897 | 13.89 | 10.255 | 10.39 | 9.25 | 12.338 | 0 |
| Short Term Debt
| 6.775 | 6.002 | 3.2 | 2.974 | 0 | 0 | 0 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 0.086 | 0.885 | 0.423 | 38.992 | 0 | 0 | 0 |
| Other Current Liabilities
| 24.321 | 33.741 | 34.296 | 41.964 | 23.829 | 17.121 | 0.002 |
| Total Current Liabilities
| 37.079 | 54.518 | 48.174 | 94.32 | 33.079 | 29.459 | 0.002 |
| Non-Current Liabilities: | |||||||
| Long Term Debt
| 88.346 | 95.122 | 69.929 | 50.809 | 51.349 | 34.456 | 0 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 5.179 | 1.569 | 4.125 | 3.083 | 4.351 | 6.776 | 0 |
| Total Non-Current Liabilities
| 93.525 | 96.691 | 74.054 | 53.892 | 55.7 | 41.232 | 0 |
| Total Liabilities
| 130.604 | 151.209 | 122.228 | 148.212 | 88.779 | 70.691 | 0.002 |
| Equity: | |||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 773.855 | 0.005 |
| Common Stock
| 0.169 | 0.144 | 0.142 | 0.14 | 0.124 | 0.121 | 0.026 |
| Retained Earnings
| -1,562.233 | -1,235.98 | -903.348 | -646.343 | -396.122 | -211.528 | -0.023 |
| Accumulated Other Comprehensive Income/Loss
| -0.955 | -9.926 | -2.567 | 0.268 | 1.145 | 0.306 | -0.005 |
| Other Total Stockholders Equity
| 2,075.252 | 1,911.632 | 1,822.179 | 1,725.552 | 1,023.876 | 140.41 | -0.005 |
| Total Shareholders Equity
| 512.233 | 665.87 | 916.406 | 1,079.617 | 629.023 | 703.164 | -0.002 |
| Total Equity
| 512.233 | 665.87 | 916.406 | 1,079.617 | 629.023 | 703.164 | -0.002 |
| Total Liabilities & Shareholders Equity
| 642.837 | 817.079 | 1,038.634 | 1,227.829 | 717.802 | 773.855 | 0 |